Q/C TECHNOLOGIES, INC.
For the period ended Dec 31, 2024. Filed Apr 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Management contract or compensatory plan or arrangement.
** The schedules and exhibits to the Agreement and Plan of Merger and Reorganization have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.
SIGNATURES
In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TNF PHARMACEUTICALS, INC. | ||
| Date: April 11, 2025 | By: | /s/ Mitchell Glass |
|---|---|---|
| Name: | Mitchell Glass, M.D. | |
| Title: | President and Chief Medical Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Mitchell Glass | President, Chief Medical Officer and Director | April 11, 2025 |
| Christopher C. Chapman, M.D. | (Principal Executive Officer) | |
| /s/ Ian Rhodes | Interim Chief Financial Officer | April 11, 2025 |
| Ian Rhodes | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Joshua Silverman | Chairman of the Board | April 11, 2025 |
| Joshua Silverman | ||
| /s/ Bill J. White | Director | April 11, 2025 |
| Bill J. White | ||
| /s/ Christopher C. Schreiber | Director | April 11, 2025 |
| Christopher C. Schreiber | ||
| /s/ Jude Uzonwanne | Director | April 11, 2025 |
| Jude Uzonwanne | ||
| /s/ Craig Eagle | Director | April 11, 2025 |
| Craig Eagle, M.D. | ||
Index to Consolidated Financial Statements
| Report of Independent Registered Public Accounting Firm (PCAOB ID No: 03523) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID No: 00536) | F-4 |
| Consolidated Balance Sheets | F-7 |
| Consolidated Statements of Comprehensive Loss | F-8 |
| Consolidated Statements of Changes in Stockholders’ Equity | F-9 |
| Consolidated Statements of Cash Flows | F-11 |
| Notes to Consolidated Financial Statements | F-12 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.